J&J Gene Therapy for Rare, Progressive Vision-Loss Disorder Fails Phase 3 Test

May 5, 2025
, 9:45 pm

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Johnson & Johnson’s gene therapy for X-linked retinal pigmentosa did not meet the main vision goal of a pivotal study. J&J secured full rights to the program from gene therapy biotech MeiraGtx in 2023.

The post J&J Gene Therapy for Rare, Progressive Vision-Loss Disorder Fails Phase 3 Test appeared first on MedCity News.

Leave a Replay

HHS Health IT Innovation Exec Joins INVEST Agenda at Critical Time for the Department

MedCity Pivot: How Veradigm Aims to Close the Information Gap

Assessing the validity of ICD-10 administrative data in coding comorbidities

Sign up for our Newsletter

HealthGility provides healthcare organizations with a solution for patient protected health information disclosure and confidentiality that reduces workloads and ensures the safe and secure sharing of sensitive data between different providers.

J&J Gene Therapy for Rare, Progressive Vision-Loss Disorder Fails Phase 3 Test

Leave a Replay

Related Posts

HHS Health IT Innovation Exec Joins INVEST Agenda at Critical Time for the Department

MedCity Pivot: How Veradigm Aims to Close the Information Gap

Assessing the validity of ICD-10 administrative data in coding comorbidities

Follow Us

Sign up for our Newsletter

Our Company

Resources

Connect

© All rights reserved

Contact Us